Protein Biomarkers Overview

Driving Excellence in Immuno-Oncology

Fact Sheet – Oncology Clinical Trials at Cerba Research

Monitoring Multiple Myeloma Patients Treated With Daratumumab: Teasing Out Monoclonal Antibody Interference

Assessing Clinical Response in Multiple Myeloma Patients Treated with Monoclonal Antibodies

Immune Cell Checkpoint Profiling of Solid Tumors

Immune checkpoint proteins are important regulators in self-tolerance but also allow cancer cells to evade immune destruction. Checkpoint inhibitor (CKI) blockade therapies can help restore antitumoral immunity. Combination blockade has demonstrated the potential to result in greater tumor growth inhibition than monotherapies in preclinical studies. Multiplex immunofluorescence offers a technical advantage by allowing for the detection of co-expression and spatial organization of multiple targets within a preserved tissue architecture on a single slide. We have developed the HISTOPROFILE®-CKI multiplex immunohistochemistry panel to offer personalized immune cell checkpoint profiling.

Case Study on Multiple Myeloma